Natco Pharma Share Price Falls Over 9% After Q4 FY26 Earnings Results: Net Profit Down 33.7% YoY

Natco Pharma Limited has announced its audited consolidated financial results for the quarter and year ended March 31, 2026.  

The company reported a significant decline in both total income and net profit for the fourth quarter and the entire fiscal year. 

Natco Pharma Q4 FY26 Earnings Results 

In the March 2026 quarter, Natco Pharma's total income decreased by 36.5% year-on-year (YoY) to ₹816.90 crore, compared to ₹1,287.30 crore in the same period last year.  

However, there was a 15.8% increase quarter-on-quarter (QoQ) from ₹705.40 crore in the December 2025 quarter.  

The net profit for the quarter fell by 33.7% YoY to ₹269 crore, down from ₹406 crore a year ago, but showed a 77.8% rise QoQ from ₹151.30 crore in the previous quarter. 

Annual Financial Results for FY26 

For the fiscal year 2026, Natco Pharma's total income saw an 8.5% decline YoY, amounting to ₹4,375.90 crore compared to ₹4,784 crore in the previous year.  

The net profit for FY26 also dropped by 24.7% YoY to ₹1,418.50 crore from ₹1,883.40 crore in FY25. 

Natco Pharma's financial results reflect a challenging year for the company, with notable declines in both quarterly and annual performance metrics. 

Read More: BEML Share Price Falls Over 6% After Q4 FY26 Earnings Results: Net Profit Down 37.5% YoY! 

NATCO Pharma Share Price Performance 

As of May 29, 2026, at 2:40 PM, NATCO Pharma share price on NSE was trading at ₹1,061.60 down by 9.71% from the previous closing price. 

Conclusion 

Natco Pharma's financial results for Q4 and FY26 indicate a downturn in both total income and net profit. The company experienced a significant YoY decline in its financial performance, although there was some QoQ improvement in the fourth quarter. These results highlight the financial challenges faced by the company during this period. 

Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.